Volume 68, Issue 4, Pages 814-826 (April 2018) Eliminating hepatitis C within low-income countries – The need to cure genotypes 4, 5, 6  Tarik Asselah, Tarek Hassanein, Imam Waked, Abdellah Mansouri, Geoffrey Dusheiko, Edward Gane  Journal of Hepatology  Volume 68, Issue 4, Pages 814-826 (April 2018) DOI: 10.1016/j.jhep.2017.11.037 Copyright © 2017 Terms and Conditions

Fig. 1 HCV GT4, GT5, and GT6 distribution worldwide. HCV GT4, GT5, and GT6 infect an estimated 30 million people worldwide and account for approximately 20% of global HCV infections. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions

Fig. 2 Mode of action of direct-acting antivirals (DAAs) and developmental milestones of approved DAAs. (A) DAA with different viral targets (NS3 protease inhibitors, nucleoside/nucleotide analogues and non-nucleoside inhibitors of the RNA-dependent RNA polymerase and NS5A inhibitors) have been developed in combination and leads to high efficacy, reduced risk of resistance and shorten treatment duration. (B) Development milestones of approved DAAs. DAA, direct-acting antiviral; DCV, daclatasvir; DSV, dasabuvir; EBV, elbasvir; GLE, glecaprevir; GRZ, grazoprevir; GT, genotype; LDV, ledipasvir; NS, non-structural protein; OMV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RBV, ribavirin; RTV, ritonavir; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir; VOX, voxilaprevir. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions

Fig. 3 Treatment with DAAs results in high rates of cure in people who inject drugs.85–88 DAA, direct-acting antiviral; DSV, dasabuvir; EBV, elbasvir; GRZ, grazoprevir; LDV, ledipasvir; OMV, ombitasvir; PTV, paritaprevir; RBV, ribavirin; RTV, ritonavir; SOF, sofosbuvir; SVR12, sustained virological response at week 12; VEL, velpatasvir. Journal of Hepatology 2018 68, 814-826DOI: (10.1016/j.jhep.2017.11.037) Copyright © 2017 Terms and Conditions